Purinergic receptor signaling in breast cancer is a unique niche, where a few groups have found the involvement of the ATP-activated P2Y2 receptor and relatively long-term cancer phenotypes that occur over hours to days, like epithelial-to-mesenchymal transition (EMT), migration, and invasion [18,20,29,40,41]. Here, P2RY2 is linked to breast carcinoma.